NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
December 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 27, 2024 07:01 ET
|
NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
November 13, 2024 16:14 ET
|
NurExone Biologic Inc
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
October 23, 2024 02:56 ET
|
NurExone Biologic Inc
NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
September 26, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
September 12, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
September 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 28, 2024 08:34 ET
|
NurExone Biologic Inc
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
August 23, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
August 15, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency